[go: up one dir, main page]

TN2012000473A1 - Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs - Google Patents

Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Info

Publication number
TN2012000473A1
TN2012000473A1 TNP2012000473A TN2012000473A TN2012000473A1 TN 2012000473 A1 TN2012000473 A1 TN 2012000473A1 TN P2012000473 A TNP2012000473 A TN P2012000473A TN 2012000473 A TN2012000473 A TN 2012000473A TN 2012000473 A1 TN2012000473 A1 TN 2012000473A1
Authority
TN
Tunisia
Prior art keywords
robo1
tumors
treatment
fusion protein
protein
Prior art date
Application number
TNP2012000473A
Other languages
English (en)
Inventor
Francis Blanche
Béatrice Cameron
Tarik Dabdoubi
Frédérique Dol-Gleizes
Pierre Fons
Jean-Pascal Herault
Catherine Prades
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42830780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2012000473(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of TN2012000473A1 publication Critical patent/TN2012000473A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne une protéine recombinante Robo1-Fc et son utilisation pour traiter les maladies dans lesquelles une protéine Slit est surexprimée, en particulier le cancer. Elle concerne également une composition comprenant une telle protéine recombinante. Un autre aspect de l'invention consiste en l'utilisation d'une molécule Robo1-Fc en tant qu'outil de diagnostic pour détecter la surexpression d'une molécule de la famille Slit chez un patient.
TNP2012000473A 2010-04-14 2012-09-28 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs TN2012000473A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1052829A FR2958936A1 (fr) 2010-04-14 2010-04-14 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
PCT/FR2011/050811 WO2011128561A1 (fr) 2010-04-14 2011-04-08 Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Publications (1)

Publication Number Publication Date
TN2012000473A1 true TN2012000473A1 (fr) 2014-01-30

Family

ID=42830780

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2012000473A TN2012000473A1 (fr) 2010-04-14 2012-09-28 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Country Status (27)

Country Link
US (1) US9493529B2 (fr)
EP (1) EP2558489A1 (fr)
JP (1) JP5858442B2 (fr)
KR (1) KR20130059329A (fr)
CN (1) CN102884076A (fr)
AR (1) AR080891A1 (fr)
AU (1) AU2011239839B2 (fr)
BR (1) BR112012026020A2 (fr)
CA (1) CA2796303A1 (fr)
CL (1) CL2012002879A1 (fr)
CR (1) CR20120508A (fr)
DO (1) DOP2012000265A (fr)
EA (1) EA201291044A1 (fr)
EC (1) ECSP12012230A (fr)
FR (1) FR2958936A1 (fr)
GT (1) GT201200275A (fr)
IL (1) IL222382A (fr)
MA (1) MA34221B1 (fr)
MX (1) MX338981B (fr)
NI (1) NI201200155A (fr)
PE (1) PE20130199A1 (fr)
PH (1) PH12012502044A1 (fr)
SG (1) SG184529A1 (fr)
TN (1) TN2012000473A1 (fr)
TW (1) TW201142024A (fr)
UY (1) UY33334A (fr)
WO (1) WO2011128561A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1064093C (zh) 1993-04-05 2001-04-04 达金工业株式会社 聚四氟乙烯棉状物及其制造方法
UY33833A (es) * 2010-12-23 2012-07-31 Sanofi Sa Proteína de fusión Robo1-Fc para su uso en el tratamiento del hepatocarcinoma
CA2860558C (fr) 2012-01-05 2021-03-02 Boston Medical Center Corporation Signalisation de slit-robo pour le diagnostic et le traitement d'une maladie renale
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
WO2017194597A1 (fr) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Matrice de séparation
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
WO2017194592A1 (fr) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Procédé de conservation d'une matrice de séparation
ES2909833T3 (es) 2016-05-11 2022-05-10 Cytiva Bioprocess R & D Ab Método de limpieza y/o desinfección de una matriz de separación
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
MX2019014480A (es) * 2017-06-02 2020-01-23 Pfizer Proteinas recombinantes robo2, composiciones, metodos y usos de las mismas.
US11406682B2 (en) 2017-08-24 2022-08-09 Bar-Ilan University Roundabout (Robo) receptor inhibitors and uses thereof
JP7340027B2 (ja) * 2019-02-27 2023-09-06 デウン ファーマシューティカル カンパニー リミテッド アルブミンと結合したＳｌｉｔ３タンパク質のＬＲＲＤ２を含む骨関連疾患の予防または治療用組成物
AU2020262256B2 (en) 2019-04-23 2026-01-15 The Regents Of The University Of California Compositions and methods useful in promoting milk production
WO2025056020A1 (fr) * 2023-09-14 2025-03-20 北京拓界生物医药科技有限公司 Protéine contenant un domaine robo et son utilisation médicale

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
WO1999020764A1 (fr) * 1997-10-20 1999-04-29 The Regents Of The University Of California Robo : une famille de polypeptides et d'acides nucleiques impliques dans le guidage des nerfs
CA2324284A1 (fr) * 1998-04-02 1999-10-14 Rigel Pharmaceuticals, Inc. Peptides provoquant la formation de structures compactes
CA2416732C (fr) * 2000-08-02 2016-02-09 Brad St. Croix Profils d'expression de cellules endotheliales
EP2316853A3 (fr) 2002-03-08 2011-10-05 Shanghai Institutes for Biological Sciences, CAS Detection et modulation de l'angiogenese provoquee par une mediation des slit et des robo, et utilisations correspondantes
JP4643450B2 (ja) * 2003-08-08 2011-03-02 株式会社ペルセウスプロテオミクス 癌高発現遺伝子
CN1926237A (zh) * 2004-01-28 2007-03-07 森托尼克斯制药有限公司 用于治疗不育症的异二聚体促卵泡激素－Fc(FSH－Fc)融合蛋白
EP2738178A1 (fr) * 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Purification d'anticorps
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
US20130195881A1 (en) * 2007-04-27 2013-08-01 Sanjaya Singh Potent, stable and non-immunosuppressive anti-cd4 antibodies
DK2195023T3 (en) 2007-08-29 2018-06-18 Sanofi Sa HUMANIZED ANTI-CXCR5 ANTIBODIES, DERIVATIVES THEREOF AND THEIR USE
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent

Also Published As

Publication number Publication date
US9493529B2 (en) 2016-11-15
US20130039912A1 (en) 2013-02-14
PH12012502044A1 (en) 2017-07-26
IL222382A (en) 2016-06-30
FR2958936A1 (fr) 2011-10-21
JP2013523172A (ja) 2013-06-17
AR080891A1 (es) 2012-05-16
CL2012002879A1 (es) 2013-03-22
DOP2012000265A (es) 2013-02-28
BR112012026020A2 (pt) 2016-06-28
MX2012011822A (es) 2012-11-12
ECSP12012230A (es) 2012-11-30
CN102884076A (zh) 2013-01-16
KR20130059329A (ko) 2013-06-05
JP5858442B2 (ja) 2016-02-10
IL222382A0 (en) 2012-12-31
MX338981B (es) 2016-05-06
PE20130199A1 (es) 2013-03-09
NI201200155A (es) 2013-02-05
CR20120508A (es) 2012-11-01
EP2558489A1 (fr) 2013-02-20
GT201200275A (es) 2014-01-24
AU2011239839B2 (en) 2015-08-20
CA2796303A1 (fr) 2011-10-20
UY33334A (es) 2011-12-01
EA201291044A1 (ru) 2013-04-30
TW201142024A (en) 2011-12-01
SG184529A1 (en) 2012-11-29
WO2011128561A1 (fr) 2011-10-20
AU2011239839A1 (en) 2012-11-08
MA34221B1 (fr) 2013-05-02

Similar Documents

Publication Publication Date Title
TN2012000473A1 (fr) Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
WO2007091250A8 (fr) Enzymotherapie de remplacement pour le traitement des maladies lysosomiales
PE20110217A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
WO2004108139A3 (fr) Utilisation de composes heterocycliques en tant qu'inhibiteurs de scce
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
MA33566B1 (fr) Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux
DE60028970D1 (de) An her2 bindende peptidverbindungen
CL2012000592A1 (es) Compuestos derivados de fenoxi o fenil-tieno[3,2-b]piridina, inhibidores de tirosina quinasas; composicion farmaceutica; y su uso en el tratamiento de cancer colorrectal, de pulmon, hematologico, de higado, mama, en retinopatia diabetica, degeneracion macular, glaucoma, psoriasis, diabetes, enfermedades neurodegenerativas, entre otras.
NO20054958L (no) Substitulerte aminokarboksylsyrer
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
NO20054957L (no) Subtituerte karboksylsyrer
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
EP2285989A4 (fr) Nouvelles cibles permettant de réguler l'angiogenèse
WO2008153933A3 (fr) Protéines à variante d'épissure her2 et her3 solubles, oligonucléotides à permutation d'épissage et leur utilisation thérapeutique
GEP20125647B (en) Kinesin inhibitors as cancer therapeutics
TW200630327A (en) Substituted phenylalkanoic acids
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
WO2008060945A3 (fr) Diagnostic et traitement du cancer du sein
WO2001071357A3 (fr) Proteines, genes et leur utilisation pour diagnostiquer et traiter le cancer de la poitrine
Zhu et al. Inhibition of PINK1 senses ROS signaling to facilitate neuroblastoma cell pyroptosis
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
MA34291B1 (fr) Compositions et méthodes de diagnostic et de traitement d'une tumeur
EP4218786A3 (fr) Opiorphine destinée à être utilisée comme agent analgésique
MA34480B1 (fr) Docosahexanoate de panthényle et son utilisation pour traiter et prévenir les maladies cardiovasculaires
TW200631949A (en) Substituted carboxylic acids